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Abstract
Chronic urticaria is a spontaneous or inducible group of diseases characterized
by the occurrence of wheals (and, in about half of cases, angioedema) for more
than 6 weeks. These are rather frequent conditions that may severely affect
patients’ quality of life and sometimes represent a challenge for doctors as well.
The causes of chronic urticaria are still poorly defined, although there is
growing evidence that different biologic systems including immunity,
inflammation, and coagulation may take part in the pathomechanism eventually
leading to mast cell and basophil degranulation and hence to wheal formation.
This review will discuss the main findings that are (slowly) shedding light on the
pathogenesis of this disorder.
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Introduction
Chronic urticaria, defined as the recurrent occurrence of wheals 
with or without angioedema for longer than 6 weeks, can be clas-
sified into spontaneous or inducible based on the absence or pres-
ence of identifiable physical stimuli able to elicit the skin lesions1. 
While there is little doubt that the release of histamine by mast cells 
and basophils represents the final stage in the pathomechanisms 
involved in this group of diseases, there is still some uncertainty 
about the factors activating these cells and eventually inducing 
their degranulation. Several lines of evidence indicate that differ-
ent biologic systems like immunity, inflammation, and coagulation 
may contribute to a common mechanism leading to wheal genera-
tion. This short commentary will summarize the current knowledge 
about the mechanisms theoretically leading to histamine release in 
chronic urticaria.
Established facts
The bulk of studies carried out during the last 30 years have shown 
that different biologic systems (i.e. autoimmunity, auto-allergy, 
inflammation, and coagulation) may concur to produce the wheal 
and flare lesions as well as the angioedema that characterize chronic 
urticaria. For clarity, these biologic systems, which are largely 
linked with each other, along with the main cell lines involved 
in either their activation or their behavior as effector cells will be 
considered singularly in the following subsections.
Autoreactivity/autoimmunity
More than 30 years ago, Grattan and co-workers demonstrated 
that the intradermal injection of autologous serum induces a 
wheal-and-flare reaction in a large proportion of patients with 
chronic urticaria2; this led them to conclude that chronic urticaria 
is characterized by circulating histamine-releasing factors. Since 
then, a positive autologous serum skin test (ASST) has been con-
sidered as a marker of “autoreactivity”. This in vivo test is quite 
easy to perform and seems sufficiently specific for chronic urti-
caria, as normal subjects do not show any skin reactivity3, although 
it may score positive in inducible urticarias such as cold urticaria4 
as well as in some other “allied” conditions, such as the multiple 
drug allergy syndrome and multiple hypersensitivity to non- 
steroidal anti-inflammatory drugs5,6. However, the ASST scores 
positive in only about one half of chronic urticaria patients7,8, 
leaving a large proportion of patients who do not show any autore-
activity despite their maybe severe and ongoing disease.
Following the first observation on skin reactivity to autologous 
serum that remains a cornerstone in urticaria research, the second 
important step in the definition of the pathogenic mechanism was 
the demonstration of histamine-releasing autoantibodies about 
20 years ago, suggesting an autoimmune origin. This was based 
on the detection of circulating and functionally active IgG autoan-
tibodies directed against either the high-affinity IgE receptor 
(FcεRI) present on both mast cells and basophils (in most cases) or 
membrane-bound IgE (in a minority of patients)9–12.
Although this was a fascinating explanation for the ongoing his-
tamine release, several subsequent studies found that this mecha-
nism is in fact viable in only a minority of patients8,13. Furthermore, 
both types of autoantibodies have been detected with similar fre-
quency in chronic urticaria patients and controls without chronic 
urticaria13. Nonetheless, in more recent times, the autoimmune 
pathogenesis hypothesis has received new, indirect but strong sup-
port from the detection of circulating autoreactive CD4+ T cells that 
proliferate in response to FcεRI in >50% of patients with chronic 
urticaria examined14.
Basophils: their pathogenic role and use in chronic urticaria 
diagnosis
Although there is little doubt that the mast cell is the main final 
effector cell in chronic urticaria, basophils and their role in the 
disease have received much attention during the last decade. It is 
well known that active chronic urticaria is characterized by baso-
penia due to the elective recruitment of circulating basophils into 
the skin lesions15 and that basopenia is directly related to disease 
severity. Recent studies found that chronic urticaria blood basophils 
show a reduced surface expression of CRTH2 (the chemoattractant 
receptor–homologous molecule expressed on TH2 cells), the 
receptor for prostaglandin D2 (PGD2). It is therefore possible that 
decreased CRTH2 levels on basophils in patients with chronic urti-
caria are due to in vivo PGD2-mediated activation, suggesting the 
engagement of CRTH2 in patients with chronic urticaria16. Fur-
thermore, basophils from chronic urticaria patients show differ-
ent phenotypes (either responder or non-responder, based on the 
degranulation response to polyclonal goat anti-human IgE) that 
seem independent of the presence of IgG autoantibodies to IgE 
or FcεRI and seem stable during active disease13,17, and their IgE 
receptor-mediated degranulation is enhanced during disease 
remission13,17.
The finding that at least a proportion of chronic urticaria patients 
show autoimmune phenomena targeting mast cells and basophils 
has led to the investigation of the diagnostic accuracy of basophil-
based in vitro tests aiming to diagnose autoimmunity. The first 
test used was the time-consuming and cumbersome basophil his-
tamine release assay (BHRA), first introduced in the 1960s and 
subsequently marketed as a more convenient testing kit18; on the 
other hand, the observation that chronic urticaria sera were able to 
induce the surface expression of basophil activation markers such 
as CD6319 led to the investigation of the diagnostic usefulness of 
the basophil activation test (BAT) measuring CD63 and CD203c 
surface expression by flow cytometry20,21. However, in view of the 
fact that no more that 50% of chronic urticaria patients have an 
autoimmune disease and of the intrinsic variability of basophil 
releasability, the clinical usefulness of these tests has been 
questioned22 and they have not reached the status of routine investi-
gation for this disease.
Auto-allergy
Another important step was the discovery of specific IgE for thy-
roid peroxidase (TPO) for dsDNA and ssDNA, which has recently 
provided a different mechanism potentially able to promote the sur-
vival, proliferation, and activation of mast cells23. This pathogenic 
mechanism could be classified as “auto-allergic” and autoimmune 
at the same time. However, the proportion of patients in whom  such 
IgE autoantibodies can be detected is limited, and TPO-specific 
IgE autoantibodies are generally associated with the more com-
mon TPO IgG autoantibodies that characterize patients with 
Hashimoto’s thyroiditis which are found in a minority of patients. 
However, research in this field is very active, and it cannot be 
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excluded that other “auto-allergens” will be detected in larger 
proportions of patients with chronic urticaria in the near future24.
Inflammation
It is increasingly clear that chronic urticaria is characterized by a 
systemic pro-inflammatory state. The studies showing increased 
levels of different single markers of inflammation (e.g. matrix 
metalloproteinase and others) that have appeared in the medi-
cal literature over the years will not be reviewed in detail here. 
Recent studies showed the co-existence of chronic urticaria and 
metabolic syndrome (MS) in a Korean population25; patients with 
both chronic urticaria and MS were older, had a more severe dis-
ease, had higher levels of inflammation markers (i.e. eosinophil 
cationic  protein [ECP], tumor necrosis factor [TNF]-alpha, and 
complement), and, interestingly, more frequently scored negative 
on the ASST than those without MS. In another Asian-based 
population study, chronic urticaria was more frequent among sub-
jects with a prior diagnosis of hyperlipidemia26. Recently, chronic 
urticaria patients were found to show increased levels of a series 
of  adipokines (lipocalin-2, TNF-alpha, IL-6, and IL-10) but lower 
levels of adiponectin27. The findings with IL-6 are in keeping with 
a previous study28 showing an association between IL-6 and disease 
severity.
Coagulation
The observation that the autologous plasma skin test (APST) may 
score positive in some ASST-negative patients29 has prompted 
investigation of the coagulation system in patients with chronic 
urticaria. Specific studies have shown that the coagulation cascade 
is activated in chronic urticaria and involves the extrinsic pathway 
first and the intrinsic pathway second29–32. The process seems to be 
triggered by the hyper-expression of tissue factor by activated eosi-
nophils33 and parallels disease activity. IgG autoantibodies to the 
low-affinity IgE receptor FcεRII, which is present on the membrane 
of eosinophils, have been detected in quite a large proportion of 
patients (about 65%) with chronic urticaria34 and might be involved 
in the activation of such cells with subsequent release of major basic 
protein and other mediators causing mast cell degranulation. The 
activation of the coagulation cascade might potentially play a rel-
evant pathogenic role if one considers that thrombin can markedly 
increase the vascular permeability and is a potent inducer of mast 
cell degranulation in experimental models. The activation of the 
coagulation cascade occurs in other skin disorders characterized by 
an increase of vascular permeability, such as angioedema due to 
C1-inhibitor deficiency and bullous pemphigoid35,36, but also in a 
wide spectrum of systemic diseases, such as disseminated intravas-
cular coagulation37, deep venous thrombosis38, and endotoxemia39, 
all prothrombotic conditions that are not characterized by urti-
caria or edema. However, the activation of coagulation should not 
necessarily be considered a non-specific phenomenon but rather a 
common intermediate step occurring in the pathophysiology of 
different diseases. Thus, the involvement of coagulation is another 
piece of truth unable to explain the whole story.
Other mechanisms
Quite recently, we were able to show that sera from patients with 
chronic urticaria induce significant activation of mast cells lack-
ing the high-affinity IgE receptor, irrespective of the autoreactivity 
status or of the presence/absence of circulating autoantibod-
ies40. This fact suggests a pathomechanism that bypasses the IgE 
receptor mechanism. In subsequent studies, we showed that 
low-molecular-weight circulating factors (molecular weight about 
30 kDa) may be involved in the activation of mast cells in chronic 
urticaria patients41, thus confirming very old data by Grattan and 
co-workers42.
Using the response to omalizumab as a means to 
distinguish different chronic urticaria phenotypes
Omalizumab was recently licensed for the treatment of chronic 
urticaria. All three phase III studies as well as the real-life stud-
ies carried out in large numbers of patients have demonstrated 
that this humanized monoclonal IgG antibody to IgE is highly 
effective in a large proportion of patients with chronic urticaria 
who don’t show any clinical response to second-generation anti-
histamines given at doses even higher than licensed ones. The 
pattern of response to this drug has indirectly led to the categori-
zation of patients with severe disease into “fast responders” (sub-
jects who show a complete response as short as 3–7 days after the 
first administration of the drug; these represent about 60–70% 
of patients), “slow responders” (subjects who need three to five 
monthly administrations before showing a significant clinical 
response; about 10–20% of cases), and “non-responders” (about 
10–20% of cases)43. It is easy to speculate that different pathogenic 
mechanisms might underlie the different patterns of response. 
Several potential markers of response to omalizumab treatment 
have been investigated so far. In one study looking at the poten-
tial use of a CD203c assay (the so-called BAT) as a biomarker 
of responsiveness to omalizumab, it was found that the lack of 
basophil CD203 upregulating activity was associated with a 
higher likelihood of response to the drug44. This observation seems 
to agree with the results of another study finding that a positive 
response to omalizumab was associated with a negative histamine 
release assay45. On the other hand, Gericke and co-workers 
found that a positive BHRA, which was associated with a posi-
tive ASST, was frequently observed in “slow responders” to 
omalizumab43. Another interesting observation is that omalizumab 
has been found to be effective not only in the spontaneous form but 
also in several inducible forms of chronic urticaria46,47. This sug-
gests that the drug interferes with a common pathogenic mecha-
nism underlying a proportion of both spontaneous and inducible 
urticarias. Notably, the fact that the symptomatic cold urticaria, 
a frequent chronic inducible urticaria, can be passively transmit-
ted to normal subjects via the serum of affected individuals has 
been known for many years. Since the mechanism of action of 
omalizumab in urticaria is all but elucidated, the next few years 
will probably shed some light on these questions.
Conclusions
The pathogenesis of chronic urticaria is probably characterized 
by a multiplicity of mechanisms, including autoimmunity, auto-
allergy, and coagulation, each of which may carry different weight 
in each patient. Much research is in progress, and the overall 
perception is that the solution to the puzzle is not too far away.
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